David J. St. Jean
Scorpion Therapeutics (United States)(US)
Publications by Year
Research Areas
Metabolism, Diabetes, and Cancer, Pancreatic function and diabetes, PI3K/AKT/mTOR signaling in cancer, Hormonal Regulation and Hypertension, Advanced Breast Cancer Therapies
Most-Cited Works
- → Mitigating Heterocycle Metabolism in Drug Discovery(2012)250 cited
- → From Fragment Screening to In Vivo Efficacy: Optimization of a Series of 2-Aminoquinolines as Potent Inhibitors of Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1)(2011)136 cited
- → Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors(2013)97 cited
- → Discovery of a Potent, Orally Active 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor for Clinical Study: Identification of (S)-2-((1S,2S,4R)-Bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221)(2010)80 cited
- → Toward a General Route to the Eunicellin Diterpenes: The Asymmetric Total Synthesis of Deacetoxyalcyonin Acetate(2004)70 cited
- → A Tandem Cross-Coupling/SNAr Approach to Functionalized Carbazoles(2007)64 cited
- → STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts(2023)63 cited
- → Samarium(II) Iodide-Mediated Intramolecular Conjugate Additions of α,β-Unsaturated Lactones(2002)59 cited
- → Small Molecule Disruptors of the Glucokinase–Glucokinase Regulatory Protein Interaction: 3. Structure–Activity Relationships within the Aryl Carbinol Region of the N-Arylsulfonamido-N′-arylpiperazine Series(2014)52 cited
- → 2-(S)-Phenethylaminothiazolones as Potent, Orally Efficacious Inhibitors of 11β-Hydroxysteriod Dehydrogenase Type 1(2007)50 cited